Point72 Asia (Singapore) Pte. Ltd. C4 Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 21,708 shares of CCCC stock, worth $53,618. This represents 0.01% of its overall portfolio holdings.
Number of Shares
21,708
Previous 43,447
50.04%
Holding current value
$53,618
Previous $62.1 Million
22.43%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
109Shares Held
55.4MCall Options Held
329KPut Options Held
186K-
Lynx1 Capital Management LP San Juan, PR7.1MShares$17.5 Million3.06% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.05MShares$17.4 Million0.95% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.24MShares$12.9 Million0.4% of portfolio
-
Morgan Stanley New York, NY4.97MShares$12.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$12 Million0.06% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $121M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...